Trial Profile

A first-in-human study phase 1b study of APG279 (APG777 + APG990) against DUPIXENT in moderate-to-severe AD

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 06 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs APG-279 (Primary) ; Dupilumab
Indications Atopic dermatitis
Focus Adverse reactions; First in man
Sponsors Apogee Therapeutics

Most Recent Events

06 Mar 2025 New trial record
03 Mar 2025 According to an Apogee Therapeutics media release, APG279 (APG777 + APG990) Phase 1b against DUPIXENT now supported by positive, interim Phase 1 results for APG990 and completion of a combination toxicology study.
03 Mar 2025 According to an Apogee Therapeutics media release, company plans to initiate this trial in 2025 and interim readout expected in the second half of 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com